Lilly cuts 250 jobs and invests €100m at French site

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Filipefrazao)
(Image: Getty/Filipefrazao)

Related tags: Eli lilly, France, Diabetes

Lilly France announced 250 positions will be cut from its Fegersheim site but will also invest €100m to update facilities over the coming years.

Local media reports revealed the decision was based on a ‘transformative project’ for the Fegersheim site, which produces injectable drugs and employs approximately 1,400 staff.

In a statement, the company said that external pressures on the pricing of products necessitate the reduction of production costs.

The €100m ($114m) investment will see the company focus on bringing in new technology, which will also require the recruitment of staff members with the necessary skills. The funding for the site update will be provided through to 2021.

As a result, the company revealed that 25 new recruits will be hired. However, 250 members of the current site team would have their positions terminated by the end of 2020.

The facility will focus on the manufacture of ‘connected medicine’ for diabetes.

The company has been looking externally to develop innovative means of treating diabetes, such as its licensing deal with Sigilon Therapeutics for its cell therapy treatment​.

Related news

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Follow us


View more